





Instructions for completing the VITRAKVI® (larotrectinib) prescription and patient support program enrollment form

Please complete the following short steps to enroll your patients in support services available through TRAK Assist™ for VITRAKVI.





VITRAKVI Prescription

Prescriber completes the Patient Contact Information, Prescriber Contact Information, Diagnostics Information, and Prescription Information sections, and signs and dates where indicated

STEP 2

Patient Support Opt-In

Patient checks the services he/she wishes to receive, initials where indicated, and signs and dates the "Written Permission to Share Protected Health Information"

STEP STEP

Submission

Fax the form, along with copies of the patient's pharmacy insurance card(s) (front and back), to 1-888-506-TRAK (1-888-506-8725)

For more information and assistance completing the form, please call **1-844-634-TRAK** (1-844-634-8725). Additional copies of the form are available at VITRAKVI.com.

Please see Indication and full Important Safety Information on page 5 and accompanying full Prescribing Information.











VITRAKVI® (larotrectinib) prescription and patient support program enrollment form

PATIENT CONTACT INFORMATION

Patient name*		_ DOB*	/ / IM/DD/YYYY		Male	Female
Address*	City*			State*	Zip*	
Preferred phone*	Email					
Alternate phone Please fax a copy of the patient's insurance card(s) (front and back) along with this fo						
Primary caregiver	Preferred contact metho	od				
PRIMARY PRESCRIPTION INSURER						
Prescription insurer	Phone			Policy ID _		
Group number Prescription BIN	Prescription PCN		_ Subscri	ber name		
SECONDARY PRESCRIPTION INSURER						
Prescription insurer	Phone			Policy ID _		
Group number Prescription BIN	Prescription PCN		_ Subscri	ber name _		
PRESCRIBER CONTACT INFORMATION						
Prescriber name*		. NPI*				
Name of supervising/collaborating physician (if applicable)						
Address*	City		S	tate	ZIP	
Office contact	Phone					
Fax	Email					
DIAGNOSTICS INFORMATION						
Has the patient tested positive for <i>NTRK</i> gene fusion?						
Yes. If yes, please include copy of results or provide lab name and la	b test date.					
Lab name	_ Lab test date					
○ No. If no, is assistance needed to find an appropriate lab?	s ONo					
Test type						
Next-Generation Sequencing (NGS) Fluorescence in situ hybridization Select if patient needs appeal or financial assistance with diagnostic				Polymera	se chain rea	action (PCR)
*Required field.	tion of \//TDA//// tractroops					

To report any advarge events, product technical complaints, or medication errors acceptated with the

To report any adverse events, product technical complaints, or medication errors associated with the use of VITRAKVI, contact Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

FAX THIS FORM AND THE PATIENT INSURANCE INFORMATION TO 1-888-506-TRAK (1-888-506-8725).







1-844-634-TRAK

1-888-506-TRAK



VITRAKVI® (larotrectinib) prescription and patient support program enrollment form Access. Resources. Support.

Name of patient"		DOB,/
PRESCRIPTION INFORMATION		MM/DD/YYYY
ICD-10 Diagnosis Code(s)		
Dosage Form* VITRAKVI in: 25-mg capsule 100-mg c	apsule 20-mg/mL 100 mL bottle oral s	olution
O SIG*	Quantity/Supply*	Refills
Home Healthcare Visits (physician please select an option):		
O Home healthcare nurse visit (During the home visit, the home syringes for medication withdrawal)	healthcare nurse will educate patient/caregiv	ver on insertion of adapter and use of
O Patient/caregiver will be seen in this physician's office for educ	cation on insertion of adapter and use of syri	inges for medication withdrawal
Preferred Pharmacy (not guaranteed): Accredo – Phone: 1	855-540-1797 Fax: 1-877-327-7120	
CVS Specialty – Pho	ne: 1-800-790-1698 Fax: 1-855-296-021	0
OUS Bioservices – Pho	one: 1-833-230-1407 Fax: 1-833-878-59	17
Allergies	Other medications taken	
I certify that the above therapy is medically necessary and that the I appoint TRAK Assist™, on my behalf, to convey this prescription t	· · · · · · · · · · · · · · · · · · ·	, ,
Prescriber Signature and Date* (sign and indicate the date of	n only one of the lines below; no stamps	allowed)
Dispense as written		Date
Substitutions permitted		Date
*Required field.		
OI grant permission for TRAK Assist™ to leave on the previous page, including the name of PATIENT SUPPORT PROGRAM ENROLLMENT Bayer provides patient support services for VITRAKVI and temporary assistance for eligible patients; (B) tel	the drug, if I am not available. patients that include (A) financial as	ssistance for eligible patients
patients with delays or lapses in coverage. You may a TRAK Assist counselors to contact you and discuss a resources. Any assistance provided through TRAK Assist and be billed to you or any third party. If you e which may contact you or your treating physician. En at any time by calling 1-844-634-8725 or writing to You do not have to provide HIPAA Authorization to en	enroll in one or both of these progra upport options available to you thro sist is at no cost to you, and any fre xperience an adverse event, it will b rollment will be for five years. You n : TRAK Assist, PO Box 220765, Cha	ums. Enrollment allows ugh Bayer or external se drug or resources received be forwarded to Bayer Drug Safet nay opt out of this program urlotte, NC 28222-0765.
Enroll me in (check all that apply): (A) Finance	cial Assistance (B) Bridge Pr	rogram
Please initial here to confirm your elections		
To report any adverse events product technical complaints or me	dication arrare accociated with the use of VI	TD \ \L\ \/ \

FAX THIS FORM AND THE PATIENT INSURANCE INFORMATION TO 1-888-506-TRAK (1-888-506-8725).

(larotrectinib) 25-mg/100-mg CAPSULES 20-mg/mL ORAL SOLUTION

contact Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.





1-888-506-TRAK

Access. Resources. Support.

TRAKAssist VITRAKVI® (larotrectinib) prescription and patient support program enrollment form

DOB* ___ Name of patient*

WRITTEN PERMISSION TO SHARE PROTECTED HEALTH INFORMATION

I authorize the use and disclosure of my Protected Health Information ("PHI") as defined by the Health Insurance Portability and Accountability Act of 1996, which was amended by the Health Information Technology for Economic and Clinical Health Act (as amended, "HIPAA"). I understand that Protected Health Information is health information that identifies me or that could reasonably be used to identify me and that this authorization to release my information is voluntary.

I authorize my healthcare provider, including my physician, pharmacies and my health plan, to disclose my name, address, and telephone number along with certain medical information including my treatment, my eligibility for assistance, the coordination of my treatment, the receipt of my medication and my participation in the Patient Support Program, TRAK Assist, to Bayer and its agents.

I allow the use and disclosure of my PHI for the following purposes: (1) To verify my insurance information; (2) to ensure the accuracy and completeness of the TRAK Assist enrollment form; (3) to help with my reimbursement questions; (4) to determine if I qualify for patient assistance; (5) to determine my eligibility for other sources of funding; (6) to provide education, training, and ongoing support on the use of my medication; (7) to send me information on related products and services related to my treatment; (8) to send me refill reminders for my prescription and to encourage appropriate use; (9) to communicate with me, my healthcare providers and health plan insurers about my medical care and treatment; (10) to contact me for market research feedback; (11) for sales support purposes and (12) to comply with applicable law.

This authorization shall be in effect for 10 years from the date of my signature, or the date of last enrollment, whichever comes first, unless a shorter period is required by law. If I (or my representative) revoke this authorization, healthcare providers will stop using my PHI for the purposes outlined in this authorization, but the revocation will not affect prior use or disclosure of my PHI in reliance on this authorization. I (or

my representative) may revoke this authorization at any time by calling 1-844-634-8725 or writing to: TRAK Assist. PO Box 220765, Charlotte, NC 28222-0765.

I also understand that, under this authorization, entities that receive my PHI may not be required by law to keep the information private and it will no longer be protected by the privacy law. It may become available in the public domain.

I understand that I do not need to sign this form to receive medical treatment or medication. I (or my representative) have read and understand the terms of this authorization form. and have had an opportunity to ask questions about the uses and disclosures of PHI described above. All of my questions have been answered to my satisfaction. I authorize the use and disclosure of my information as described in this form.

I (or my representative) have the right to receive a copy of this authorization upon request. I understand that my healthcare providers, insurers, and health plans may receive remuneration (payment) from Bayer in exchange for disclosing my PHI to Bayer.

Patient or Patient Representative Signature

Date						
Name of Patient Representative						
Relation to Patient [‡]						

*If signed by the Patient's Representative, a description of the representative's relationship to the Patient and such person's authority to act for the Patient must be provided in the space above.

To report any adverse events, product technical complaints, or medication errors associated with the use of VITRAKVI, contact Bayer at 1-888-842-2937, or send the information to DrugSafety.GPV.US@bayer.com.

FAX THIS FORM AND THE PATIENT INSURANCE INFORMATION TO 1-888-506-TRAK (1-888-506-8725).

